Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Gene Review:

ESCO1 - establishment of sister chromatid cohesion...

Homo sapiens

Synonyms: A930014I12Rik, CTF, CTF7 homolog 1, ECO1, ECO1 homolog 1, ...

Hou, F. et al., Jäger, E. et al., Dutoit, V. et al., Maraskovsky, E. et al., Stockert, E. et al., et al.

Stockert, Jäger, Chen, Scanlan, Gout, Karbach, Arand, Knuth, Old, Maraskovsky, Sjölander, Drane, Schnurr, Le, Mateo, Luft, Masterman, Tai, Chen, Green, Sjölander, Pearse, Lemonnier, Chen, Cebon, Suhrbier, Jäger, Gnjatic, Nagata, Stockert, Jäger, Karbach, Neumann, Rieckenberg, Chen, Ritter, Hoffman, Arand, Old, Knuth,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of ESCO1

The frequency of NY-ESO-1 antibody was 9.4% in melanoma patients and 12.5% in ovarian cancer patients [1].
The cancer-testis antigen NY-ESO-1 is one of the most promising candidates for generic vaccination of cancer patients [2].
Primary peptide-specific CD8+ T-cell reactions and delayed-type hypersensitivity responses were generated in four of seven NY-ESO-1 antibody-negative patients [3].
Induction of a specific CD8+ T-cell response to NY-ESO-1 in immunized antibody-negative patients was associated with disease stabilization and objective regression of single metastases [3].
Finally, C57BL/6 mice, immunized with the NY-ESO-1 vaccine, were protected against challenge with a B16 melanoma cell line expressing NY-ESO-1 [4].

High impact information on ESCO1

As the proportion of melanomas expressing NY-ESO-1 is 20-40% and only patients with NY-ESO-1(+) tumors have antibody, this would suggest that a high percentage of patients with NY-ESO-1(+) tumors develop an antibody response to NY-ESO-1 [1].
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting [2].
Here we analyzed the CD8(+) T cell response to a NY-ESO-1 peptide vaccine composed of the two previously defined peptides 157-165 and 157-167, administered with GM-CSF as a systemic adjuvant [2].
A clinical trial was initiated to study the immunological effects of intradermal vaccination with 3 HLA-A2-binding NY-ESO-1 peptides in 12 patients with metastatic NY-ESO-1-expressing cancers [3].
In mitosis, EFO1 is phosphorylated, whereas EFO2 is degraded [5].

Biological context of ESCO1

We propose that EFO1 and EFO2 are targeted to different chromosome structures to help establish or maintain sister-chromatid cohesion [5].
The difference between EFO1 and EFO2 also is reflected in their cell cycle regulation [5].
Similar to their yeast (Eco1/Ctf7 and Eso1) and fly (deco) counterparts, both proteins feature a conserved C-terminal domain consisting of a H2C2 zinc finger motif and an acetyltransferase domain that is able to catalyze autoacetylation reaction in vitro [5].

Anatomical context of ESCO1

In vitro, the NY-ESO-1 vaccine was readily taken up by human monocyte-derived dendritic cells, and on maturation, these human monocyte-derived dendritic cells efficiently cross-presented HLA-A2-restricted epitopes to NY-ESO-1-specific CD8(+) T cells [4].
Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution [6].
Three different CD4+ T cell clones were used to mediate the specific lysis of allogeneic HLA-DP4+ Epstein-Barr virus-transformed B cells (EBV-B) pulsed with NY-ESO-1 p157-170 [7].

Analytical, diagnostic and therapeutic context of ESCO1

Antibodies to whole NY-ESO-1 were assayed by enzyme-linked immunosorbent assay [8].
Antibodies to NY-ESO-1 were found in the urine of patients whose NY-ESO-1 serum antibody titers were 1:10,000 or higher by Western blotting [9].
NY-ESO-1 is an attractive candidate tumor antigen for the development of immunotherapy for a wide variety of cancers [6].

References

A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. Stockert, E., Jäger, E., Chen, Y.T., Scanlan, M.J., Gout, I., Karbach, J., Arand, M., Knuth, A., Old, L.J. J. Exp. Med. (1998) [Pubmed]
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. Dutoit, V., Taub, R.N., Papadopoulos, K.P., Talbot, S., Keohan, M.L., Brehm, M., Gnjatic, S., Harris, P.E., Bisikirska, B., Guillaume, P., Cerottini, J.C., Hesdorffer, C.S., Old, L.J., Valmori, D. J. Clin. Invest. (2002) [Pubmed]
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Jäger, E., Gnjatic, S., Nagata, Y., Stockert, E., Jäger, D., Karbach, J., Neumann, A., Rieckenberg, J., Chen, Y.T., Ritter, G., Hoffman, E., Arand, M., Old, L.J., Knuth, A. Proc. Natl. Acad. Sci. U.S.A. (2000) [Pubmed]
NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Maraskovsky, E., Sjölander, S., Drane, D.P., Schnurr, M., Le, T.T., Mateo, L., Luft, T., Masterman, K.A., Tai, T.Y., Chen, Q., Green, S., Sjölander, A., Pearse, M.J., Lemonnier, F.A., Chen, W., Cebon, J., Suhrbier, A. Clin. Cancer Res. (2004) [Pubmed]
Two human orthologues of Eco1/Ctf7 acetyltransferases are both required for proper sister-chromatid cohesion. Hou, F., Zou, H. Mol. Biol. Cell (2005) [Pubmed]
Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution. Bownds, S., Tong-On, P., Rosenberg, S.A., Parkhurst, M. J. Immunother. (2001) [Pubmed]
HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones. Huarte, E., Karbach, J., Gnjatic, S., Bender, A., Jäger, D., Arand, M., Atanackovic, D., Skipper, J., Ritter, G., Chen, Y.T., Old, L.J., Knuth, A., Jäger, E. Cancer Immun. (2004) [Pubmed]
The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Shang, X.Y., Chen, H.S., Zhang, H.G., Pang, X.W., Qiao, H., Peng, J.R., Qin, L.L., Fei, R., Mei, M.H., Leng, X.S., Gnjatic, S., Ritter, G., Simpson, A.J., Old, L.J., Chen, W.F. Clin. Cancer Res. (2004) [Pubmed]
Urine antibody against human cancer antigen NY-ESO-1. Jäger, D., Stockert, E., Karbach, J., Herrlinger, K., Atmaca, A., Arand, M., Chen, Y.T., Gnjatic, S., Old, L.J., Knuth, A., Jäger, E. Cancer Immun. (2002) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

ESCO1	Bos taurus
ESCO1	Canis lupus familiaris
ESCO1	Gallus gallus
ESCO1	Macaca mulatta
Esco1	Mus musculus
ESCO1	Pan troglodytes
Esco1	Rattus norvegicus
RGD1562794	Rattus norvegicus

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.